Stay updated with breaking news from Hal Mackins. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cancer Research Horizons, the innovation engine at the core of the world's largest private funder of cancer research, Cancer Research UK, is partnering with Turbine,* a tech-enabled biotech leveraging
– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors –– Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeutics expertise –ALAMEDA, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXE...
— IND filing for ADU-1805 expected in Q1 2023, providing Exelixis with an opportunity to expand its clinical pipeline —— ADU-1805 may have broad applicability across multiple tumor types, including solid tumors —ALAMEDA, Calif. & ROTTERDAM, The Netherlands--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Sairopa...
– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu’s STING agonist technology, which has best-in-class potential –ALAMEDA, Calif. & KRAKOW, Poland--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and...
Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu's STING agonist technology, which